

COVID-19 Vaccinations

Subjects: Infectious Diseases

Contributor: Zhipeng Yan

Vaccination, in general, is effective in protecting high-risk populations against severe COVID-19 infections and COVID-19-associated mortality. A summary of special population groups with regards to their features, prognosis of infection, and vaccination decision based on current evidence is listed in. Patients without contraindications should be prioritized for vaccination under the careful supervision of healthcare workers after balancing the benefits and risks of vaccinations.

Keywords: COVID-19 vaccinations ; pregnancy ; frailty ; comorbidities

1. Introduction

COVID-19 has been spreading globally since late 2019 ^[1]. There is no definitive cure to date. The consequences of being infected with COVID-19 can be multi-faceted, such as multisystem inflammatory syndrome in children, acute multi-organ failure in adults, and long COVID-19 syndrome in all recoverees ^{[2][3][4][5]}. Global vaccination programs and multiple preventive measures are the most effective ways to curb rapid transmission. The progress of clinical trials has been accelerating globally to test the protective efficacy of different vaccines ^[6]. However, there remains a great hesitancy to receive the vaccines due to various reasons, such as fear of the side effects of the vaccination, especially in subjects with underlying co-morbidities ^[7]. The hesitancy rate of vaccination was found to be 19% in the United States ^[8], 35% in Ireland, and 31% in the United Kingdom ^[9]. The major factor is the uncertainty of the safety and efficacy of vaccination in high-risk groups.

2. Focus of Attention: To Receive Vaccination or Not?

Thus, geriatric populations should consider their risk factors, risk of COVID-19-associated mortality, type of vaccination, and vaccination risks and benefits before making a vaccination decision. Counseling on individual risk profile should be done by healthcare workers if in doubt.

Transplant recipients have a higher risk of severe COVID-19 infections ^{[10][11]}; they are recommended to receive vaccinations, unless there are other contraindications. Their family members should also consider vaccination to prevent cross-infection between family members.

More recently, the American Diabetic Association and Centre for Disease Control and prevention advocated prioritizing vaccination to diabetic patients in order to minimize their infection risks ^{[12][13]}.

In view of the uncertainty of the impact of COVID-19 vaccinations in pregnant women, there have been opposing opinions as to whether pregnant women should receive the vaccination. The American College of Obstetricians and Gynecologists (ACOG), American Society for Reproductive Medicine (ARSM), and the Society for Maternal–Fetal Medicine (SMFM) advocate vaccination in all pregnant and lactating women ^{[14][15][16]}, while the World Health Organization (WHO) advocates vaccinations only in high-risk pregnant women such as medical care workers or those with co-morbidities that add to the risk of severe diseases ^[17].

3. Contraindications of Vaccination

Several contraindications have been listed by guidelines and pharmaceutical companies. Absolute contraindications are listed in **Table 1**. The United States Centre for Disease Control and Prevention recommends absolute contraindications in two scenarios ^[18]: History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine. Immediate allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the COVID-19 vaccine.

Table 1. Absolute contraindications of vaccinations.

Absolute Contraindications	Type of Vaccine	Recommended Actions
Severe allergic reaction, e.g., anaphylaxis	All ^[18]	<ol style="list-style-type: none"> 1. Do not vaccinate 2. Referral to allergy immunologist 3. Consider other vaccine alternatives
Immediate allergic reaction	All ^[18]	<ol style="list-style-type: none"> 1. Risk assessment 2. Referral to allergy immunologist 3. Prolong observation period after vaccination (e.g., 30 min)

The components of the COVID-19 vaccine are listed in **Table 2**.

Table 2. Components of 24 COVID-19 vaccines with emergency use authorizations by national regulatory authorities (as at 13 September 2021). The first 7 vaccines on the table have been approved for emergency or full use by at least one WHO-recognized stringent regulatory authority (Pfizer, Moderna, Janssen, Sinovac, Oxford–AstraZeneca, Serum Institute of India Covishield, Sinopharm-BBIBP). The remaining vaccine candidates were arranged in alphabetical order.

Type of Vaccine	Active Ingredient	Inactive Ingredients
Pfizer (mRNA) ^[19] The United States	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2	<ul style="list-style-type: none"> • 2-polyethylene glycol (PEG)-2000-N, N-ditetradecylacetamide • cholesterol • 1,2-distearoyl-sn-glycero-3-phosphocholine • (4-hydroxybutyl) azanediylbis(hexane-6,1-diyl)bis(2-hexyldecanoate) • sodium chloride • monobasic potassium phosphate • potassium chloride • dibasic sodium phosphate dihydrate • sucrose

Type of Vaccine	Active Ingredient	Inactive Ingredients
Moderna (mRNA) ^[20] The United States	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2	<ul style="list-style-type: none"> • PEG2000-DMG: 1,2-dimyristoyl-rac-glycerol, methoxypolyethylene glycol • 1,2-distearoyl-sn-glycero-3-phosphocholine • cholesterol • SM102: heptadecane-9-yl 8-((2-hydroxyethyl)(6-oxo-6(undecyloxy)hexyl)amino) octanoate • tromethamine • tromethamine hydrochloride • acetic acid • sodium acetate • sucrose
Janssen (viral vector) ^[21] The United States	Recombinant, replication-incompetent Ad26 vector encoding a stabilized variant of the SARS-CoV-2 spike (S) protein	<ul style="list-style-type: none"> • polysorbate-80 • 2-hydroxypropyl-beta-cyclodextrin • citric acid monohydrate • trisodium citrate dihydrate • sodium chloride • ethanol
Sinovac/Coronavac (Vero cell) ^[22] China	Inactivated SARS-CoV-2 virus (CZ02 strain)	<ul style="list-style-type: none"> • aluminum hydroxide • disodium hydrogen dodecahydrate • sodium dihydrogen phosphate monohydrate • sodium chloride
Oxford–AstraZeneca Vaxzevria ^[23] The United Kingdom	Chimpanzee adenovirus encoding the SARS-CoV-2 Spike (S) protein ChAdOx1-S	<ul style="list-style-type: none"> • L-histidine • L-histidine hydrochloride monohydrate • magnesium chloride hexahydrate • polysorbate 80 (E 433) • sucrose • disodium edetate (dihydrate)

Type of Vaccine	Active Ingredient	Inactive Ingredients
Serum Institute of India Covishield (Oxford– AstraZeneca formulation) [24][25] India	Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike (S) protein in genetically modified human embryonic kidney 293 cells	<ul style="list-style-type: none"> • L-histidine • L-histidine hydrochloride monohydrate • magnesium chloride hexahydrate • polysorbate 80 (E 433) • sucrose • ethanol • sodium chloride • disodium edetate dihydrate (EDTA)
Sinopharm-BBIBP (inactivated virus in Vero cells) [26] China	Inactivated SARS-CoV-2 virus (HB02 strain) in Vero cell culture	<ul style="list-style-type: none"> • aluminum hydroxide adjuvant • beta-propiolactone • disodium hydrogen phosphate • sodium dihydrogen phosphate • sodium chloride
Sputnik V (viral vector) [27] Russia	Modified replication-deficient Ad26 and Ad5 encoding the SARS-CoV-2 spike(S) protein	<ul style="list-style-type: none"> • tris-(hydroxymethyl)-aminomethane • sodium chloride • sucrose • magnesium chloride hexahydrate • disodium EDTA dihydrate • polysorbate 80 • ethanol
Abdala [28][29][30] Cuba	Protein subunit vaccine containing COVID-19-derived proteins	No clinical results and information on ingredients found on electronic databases (PubMed, Google Scholar, Medline, Scopus, Embase)
Chinese Academy of Medical Sciences Covidful [31][32] China	Inactivated virus vaccine	No clinical results and information on ingredients found on electronic databases (PubMed, Google Scholar, Medline, Scopus, Embase)
Cansino Convidecia [33][34] China	Recombinant replication-deficient adenovirustype 5-vectored vaccine expressing full-length spike gene based on Wuhan-Hu-1 (Genebank accession number YP_009724390)	Details of inactive components were not listed

Type of Vaccine	Active Ingredient	Inactive Ingredients
Covaxin ^{[35][36]} , India	Whole-virion inactivated SARS-CoV-2 antigen (strain: NIV-2020770)	<ul style="list-style-type: none"> aluminum hydroxide imidazoquinolinone 2-phenoxyethanol phosphate-buffered saline
COVIran Barakat ^{[37][38]} Iran	Inactivated SARS-CoV-2 virus with Vero cell culture	<ul style="list-style-type: none"> aluminum hydroxide modified egg's medium fetal bovine serum
CoviVac ^{[39][40]} Russia	Inactivated SARS-CoV-2 virus (strain:AYDAR-1) with Vero cell culture	<ul style="list-style-type: none"> beta-propiolactone aluminum hydroxide disodium phosphate dihydrate sodium dihydrogen phosphate dihydrate sodium chloride
EpiVacCorona ^{[41][42]} Russia	Chemically synthesized peptides (short fragments of viral spike protein) conjugating to a carrier protein containing nucleocapsid proteins and maltose-binding proteins	<ul style="list-style-type: none"> L-histidine aluminum hydroxide
FAKHRAVAC ^{[43][44]} Iran	Inactivated SARS-CoV-2 virus based with cell culture	Details of ingredients not published
Medigen ^{[45][46][47]} Taiwan	Recombinant S-2P spike protein adjuvanted with CpG 1018	<ul style="list-style-type: none"> CpG 1018 aluminum hydroxide phosphate buffer solution
Minhai ^{[48][49][50]} China	Inactivated SARS-CoV-2 virus based with Vero cell culture	Details of ingredients not published
QazCovid-in ^{[51][52]} Kazakhstan	Inactivated SARS-CoV-2 virus based with cell culture	Details of ingredients not published
Sinopharm-WIBP ^{[53][54][55]} China	Inactivated SARS-CoV-2 virus (strain WIV-04) in Vero cell culture	<ul style="list-style-type: none"> aluminum hydroxide disodium hydrogen phosphate sodium dihydrogen phosphate sodium chloride
Soberana ^{[56][57][58]} Cuba	Receptor binding domain of SARS-CoV-2 spike protein conjugated chemically to tetanus toxoid	Details of ingredients not published

Type of Vaccine	Active Ingredient	Inactive Ingredients
Sputnik light ^{[59][60]} Russia	Recombinant replication-deficient Ad26 encoding the SARS-CoV-2 spike(S) protein	<ul style="list-style-type: none"> • tris-(hydroxymethyl)-aminomethane • sodium chloride • sucrose • magnesium chloride hexahydrate • disodium EDTA dihydrate • polysorbate 80 • ethanol
Zifivax ^{[61][62]} China	Recombinant tandem repeat dimeric receptor-binding domain-based protein subunit vaccine	<ul style="list-style-type: none"> • aluminum hydroxide Details of ingredients not published
ZyCoV-D ^{[63][64]} (DNA plasmid vector) India	DNA plasmid vector carrying the gene encoding the spike protein (S) of the SARS-CoV-2 virus	Details of ingredients not published

Patients with absolute contraindications should reassess their risk of vaccination and refer to an allergy immunologist. A longer observation period (e.g., 30 min) after vaccination is recommended if they have an immediate allergic reaction or minor contraindications ^[18]. They may also choose to receive alternative COVID-19 vaccination from other brands without their allergic components. Currently, 24 COVID-19 vaccines have been granted emergency use authorizations by national regulatory authorities (as at 13 September 2021). The first seven vaccines listed in **Table 2** have been approved for emergency or full use by at least one WHO-recognized stringent regulatory authority (Pfizer, Moderna, Janssen, Sinovac, Oxford–AstraZeneca, Serum Institute of India Covishield, Sinopharm-BBIBP).

References

1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* 2020, 382, 727–733.
2. McArdle, A.J.; Vito, O.; Patel, H.; Seaby, E.G.; Shah, P.; Wilson, C.; Broderick, C.; Nijman, R.; Tremoulet, A.H.; Munblit, D.; et al. Treatment of Multisystem Inflammatory Syndrome in Children. *N. Engl. J. Med.* 2021, 385, 11–22.
3. Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N. Engl. J. Med.* 2020, 383, 120–128.
4. Yan, Z.; Yang, M.; Lai, C.-L. Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. *Biomedicine* 2021, 9, 966.
5. Jain, S.; Sen, S.; Lakshmivenkateshiah, S.; Bobhate, P.; Venkatesh, S.; Udani, S.; Shobhavat, L.; Andankar, P.; Karande, T.; Kulkarni, S. Multisystem Inflammatory Syndrome in Children with COVID-19 in Mumbai, India. *Indian Pediatr.* 2020, 57, 1015–1019.
6. Yan, Z.-P.; Yang, M.; Lai, C.-L. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. *Pharmaceuticals* 2021, 14, 406.
7. Vallee, A.; Fourn, E.; Majerholc, C.; Touche, P.; Zucman, D. COVID-19 Vaccine Hesitancy among French People Living with HIV. *Vaccines* 2021, 9, 302.
8. Tsai, R.; Hervey, J.; Hoffman, K.D.; Wood, J.; Novack, J.; Johnson, J.; Deighton, D.C.; Loew, B.; Goldberg, S.L. COVID-19 Vaccine Hesitancy among Individuals with Cancer, Autoimmune Diseases, and Other Serious Comorbid Conditions. *medRxiv* 2021.
9. Murphy, J.; Vallieres, F.; Bentall, R.P.; Shevlin, M.; McBride, O.; Hartman, T.K.; McKay, R.; Bennett, K.; Mason, L.; Gibson-Miller, J.; et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. *Nat Commun.* 2021, 12, 29.

10. Caillard, S.; Chavarot, N.; Francois, H.; Maignon, M.; Greze, C.; Kamar, N.; Gatault, P.; Thaunat, O.; Legris, T.; Frimat, L.; et al. Is COVID-19 infection more severe in kidney transplant recipients? *Am. J. Transplant.* 2021, 21, 1295–1303.
11. Arya, A.; Li, M.; Aburjania, N.; Singh, P.; Royer, T.; Moss, S.; Belden, K.A. COVID-19 in Solid Organ Transplantation: Disease Severity and Clinical Update. *Transplant. Proc.* 2021, 53, 1227–1236.
12. Powers, A.C.; Aronoff, D.M.; Eckel, R.H. COVID-19 vaccine prioritisation for type 1 and type 2 diabetes. *Lancet Diabetes Endocrinol.* 2021, 9, 140–141.
13. American Diabetes Association. Diabetes and Coronavirus (COVID-19) What You Need to Know: Getting a COVID-19 Vaccine. Available online: www.diabetes.org/coronavirus-covid-19/vaccination-guide (accessed on 1 August 2021).
14. American College of Obstetricians and Gynaecologist. COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care. Available online: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care?utm_source=redirect&utm_medium=web&utm_campaign=int (accessed on 1 August 2021).
15. SMFM Society for Maternal-Fetal Medicine (SMFM) Statement: SARS-CoV-2 Vaccination in Pregnancy. Available online: <https://www.smfm.org/publications/339-society-for-maternal-fetal-medicine-smfm-statement-sars-cov-2-vaccination-in-pregnancy> (accessed on 1 August 2021).
16. ASRM American Society for Reproductive Medicine (ASRM) Position on COVID Vaccine Use in Pregnant Women. Available online: <https://www.asrm.org/news-and-publications/news-and-research/press-releases-and-bulletins/american-society-for-reproductive-medicine-asrm-position-on-covid-vaccine-use-in-pregnant-women/> (accessed on 1 August 2021).
17. W.H.O. The Moderna COVID-19 (mRNA-1273) Vaccine: What You Need to Know. Available online: <https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know> (accessed on 1 August 2021).
18. USCDC. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. 2021. Available online: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fclinical-considerations.html#Contraindications (accessed on 13 September 2021).
19. USFDA. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of The Pfizer-Biontech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19). Available online: <https://www.fda.gov/media/144413/download> (accessed on 13 September 2021).
20. USFDA. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of The Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019, (COVID-19). Available online: <https://www.fda.gov/media/144637/download> (accessed on 13 September 2021).
21. USFDA. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of The Janssen COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19). Available online: <https://www.fda.gov/media/146304/download> (accessed on 13 September 2021).
22. Ltd, S.L.S.C. COVID-19 Vaccine (Vero Cell), Inactivated (Brief version) Conditional Market Authorization. Available online: https://www.covidvaccine.gov.hk/pdf/CoronaVac_ENG_PI_brief.pdf (accessed on 13 September 2021).
23. EMA, E.M.A. Summary of Product Characteristics—AstraZeneca COVID-Vaccine 2021. Available online: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-par-product-information_en.pdf (accessed on 13 September 2021).
24. Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; Angus, B.; Babbage, G.; et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. *Lancet* 2021, 396, 1979–1993.
25. Jeewandara, C.; Kamaladasa, A.; Pushpakumara, P.D.; Jayathilaka, D.; Aberathna, I.S.; Danasekara, D.; Guruge, D.; Ranasinghe, T.; Dayarathna, S.; Pathmanathan, T.; et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. *Nat. Commun.* 2021, 12, 4617.
26. Wang, H.; Zhang, Y.; Huang, B.; Deng, W.; Quan, Y.; Wang, W.; Xu, W.; Zhao, Y.; Li, N.; Zhang, J.; et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. *Cell* 2020, 182, 713–721.e9.
27. Logunov, D.Y.; Dolzikhova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A.I.; Zubkova, O.V.; Dzharullaeva, A.S.; Kovyrshina, A.V.; Lubenets, N.L.; Grousova, D.M.; Erokhova, A.S.; et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* 2021, 397, 671–681.

28. Vie, P.c.e. Aprueba el Cecmed el Autorizo de Uso de Emergencia del Candidato Vacunal Cubano Abdala. Available online: <https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-candidato-vacunal-cubano-abdala> (accessed on 14 September 2021).
29. Reuters. Cuba Says Abdala Vaccine 92.28% Effective against Coronavirus. Available online: <https://www.reuters.com/business/healthcare-pharmaceuticals/cuba-says-abdala-vaccine-9228-effective-against-coronavirus-2021-06-21/> (accessed on 14 September 2021).
30. RPCEC, R.P.C.b.d.E.C. ABDALA Clinical Study—Phase III. Available online: <https://rpcec.sld.cu/en/trials/RPCEC00000359-En> (accessed on 14 September 2021).
31. ClinicalTrials.Gov. Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing against COVID-19-NCT04412538. Available online: <https://www.clinicaltrials.gov/ct2/show/NCT04412538> (accessed on 14 September 2021).
32. ClinicalTrials.Gov. The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing against COVID-19-NCT04659239. Available online: <https://www.clinicaltrials.gov/ct2/show/NCT04659239> (accessed on 14 September 2021).
33. Zhu, F.C.; Guan, X.H.; Li, Y.H.; Huang, J.Y.; Jiang, T.; Hou, L.H.; Li, J.X.; Yang, B.F.; Wang, L.; Wang, W.J.; et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 2020, 396, 479–488.
34. Wu, S.; Huang, J.; Zhang, Z.; Wu, J.; Zhang, J.; Hu, H.; Zhu, T.; Zhang, J.; Luo, L.; Fan, P.; et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: Preliminary report of an open-label and randomised phase 1 clinical trial. *Lancet Infect. Dis.* 2021.
35. BIOTECH. Fact Sheet For Vaccination Recipients and Caregivers: Covaxin SARS-CoV-2 Vaccine. Available online: <https://www.bharatbiotech.com/images/covaxin/covaxin-factsheet.pdf> (accessed on 14 September 2021).
36. Sapkal, G.N.; Yadav, P.D.; Ella, R.; Deshpande, G.R.; Sahay, R.R.; Gupta, N.; Vadrevu, K.M.; Abraham, P.; Panda, S.; Bhargava, B. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. *J. Travel Med.* 2021, 28, 28.
37. Mallapaty, S. Iran hopes to defeat COVID with home-grown crop of vaccines. *Nature* 2021, 596, 475.
38. Abdoli, A.; Aalizadeh, R.; Aminianfar, H.; Kianmehr, Z.; Azimi, E.; Emamipour, N.; Jamshidi, H.; Hosseinpour, M.; Taqaviani, M.; Jalili, H. Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study. *bioRxiv* 2021.
39. Kozlovskaya, L.I.; Piniaeva, A.N.; Ignatyev, G.M.; Gordeychuk, I.V.; Volok, V.P.; Rogova, Y.V.; Shishova, A.A.; Kovpak, A.A.; Ivin, Y.Y.; Antonova, L.P.; et al. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. *Emerg. Microbes Infect.* 2021, 10, 1790–1806.
40. ClinicalTrials.Gov. A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC-NCT04830800. Available online: <https://clinicaltrials.gov/ct2/show/NCT04830800> (accessed on 14 September 2021).
41. Рыжиков, А.Б.Е.А.Р.; Богрянцева, М.П.; Усова, С.В.; Даниленко, Е.Д.; Нечаева, Е.А.; Пьянков, О.В.; Пьянкова, О.Г.; Гудымо, А.С.; Боднев, С.А.; Онхонова, Г.С.; et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). *Russ. J. Infect. Immun.* 2021, 11, 283–296.
42. Ryzhikov, A.B.; Bogryantseva, M.P.; Usova, S.V.; Danilenko, E.D.; Imatdinov, I.R.; Nechaeva, E.A.; Pyankov, O.V.; Pyankova, O.G.; Gudymo, A.S.; Bodnev, S.A.; et al. Immunogenicity and Protectivity of the Peptide Vaccine against SARS-CoV-2. *Ann. Russ. Acad. Med. Sci.* 2021, 76, 5–19.
43. IRCT. Comparison of the Safety, Efficacy and Immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 Vaccines, in Adults Aged 18 and over; a Phase III Randomised, Non-Inferiority Clinical Trial. Available online: <https://en.irct.ir/trial/57980> (accessed on 14 September 2021).
44. IRCT. Phase 2 Trial of Safety and Immunogenicity of 10 Micro Gram Inactivated SARS-CoV-2 Vaccine (FAKHRAVAC), Two Doses Two Weeks Apart in Adults Aged 18–70 Years: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Available online: <https://en.irct.ir/trial/56027> (accessed on 14 September 2021).
45. Hsieh, S.M.; Liu, W.D.; Huang, Y.S.; Lin, Y.J.; Hsieh, E.F.; Lian, W.C.; Chen, C.; Janssen, R.; Shih, S.R.; Huang, C.G.; et al. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. *EClinicalMedicine* 2021, 38, 100989.
46. ClinicalTrials.Gov. A Study to Evaluate MVC-COV1901 Vaccine against COVID-19 in Adult (COVID-19)—NCT04695652, 2021. Available online: <https://clinicaltrials.gov/ct2/show/NCT04695652> (accessed on 14 September 2021).

2021).

47. ClinicalTrials.Gov. A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 against COVID-19. Available online: <https://clinicaltrials.gov/ct2/show/NCT04487210> (accessed on 14 September 2021).
48. ClinicalTrials.Gov. A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)—NCT04756323. Available online: <https://clinicaltrials.gov/ct2/show/NCT04756323> (accessed on 14 September 2021).
49. ClinicalTrials.Gov. A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and above (COVID-19)—NCT04758273. Available online: <https://clinicaltrials.gov/ct2/show/NCT04758273> (accessed on 14 September 2021).
50. ClinicalTrials.Gov. A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)—NCT04852705. Available online: <https://clinicaltrials.gov/ct2/show/NCT04852705> (accessed on 14 September 2021).
51. ClinicalTrials.Gov. Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine -NCT04691908. Available online: <https://www.clinicaltrials.gov/ct2/show/NCT04691908> (accessed on 14 September 2021).
52. ClinicalTrials.Gov. Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine—NCT04530357. Available online: <https://clinicaltrials.gov/ct2/show/study/NCT04530357?draw=2> (accessed on 14 September 2021).
53. Al Kaabi, N.; Zhang, Y.; Xia, S.; Yang, Y.; Al Qahtani, M.M.; Abdulrazzaq, N.; Al Nusair, M.; Hassany, M.; Jawad, J.S.; Abdalla, J.; et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA* 2021, 326, 35–45.
54. Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z.; et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect. Dis.* 2021, 21, 39–51.
55. Xia, S.; Duan, K.; Zhang, Y.; Zhao, D.; Zhang, H.; Xie, Z.; Li, X.; Peng, C.; Zhang, Y.; Zhang, W.; et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. *JAMA* 2020, 324, 951–960.
56. Valdes-Balbin, Y.; Santana-Mederos, D.; Quintero, L.; Fernandez, S.; Rodriguez, L.; Sanchez Ramirez, B.; Perez, R.; Acosta, C.; Méndez, Y.; Ricardo, M.G.; et al. SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies. *ACS Chem. Biol.* 2021, 16, 1223–1233.
57. Mega, E.R. Can Cuba beat COVID with its homegrown vaccines? *Nature* 2021.
58. Malik, J.A.; Mulla, A.H.; Farooqi, T.; Potttoo, F.H.; Anwar, S.; Rengasamy, K.R.R. Targets and strategies for vaccine development against SARS-CoV-2. *Biomed. Pharmacother.* 2021, 137, 111254.
59. ClinicalTrials.Gov. Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light (SPUTNIK-LIGHT)—NCT04741061, 2021 14 September 2021. Available online: <https://www.clinicaltrials.gov/ct2/show/NCT04741061> (accessed on 14 September 2021).
60. ClinicalTrials.Gov. An Open Study on the Safety, Tolerability, and Immunogenicity of “Sputnik Light” Vaccine—NCT04713488. Available online: <https://www.clinicaltrials.gov/ct2/show/NCT04713488> (accessed on 14 September 2021).
61. Zhao, X.; Zheng, A.; Li, D.; Zhang, R.; Sun, H.; Wang, Q.; Gao, G.F.; Han, P.; Dai, L. Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants. *Lancet Microbe* 2021.
62. Yang, S.; Li, Y.; Dai, L.; Wang, J.; He, P.; Li, C.; Fang, X.; Wang, C.; Zhao, X.; Huang, E.; et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. *Lancet Infect. Dis.* 2021, 21, 1107–1119.
63. Dey, A.; Chozhavel Rajanathan, T.M.; Chandra, H.; Pericherla, H.P.R.; Kumar, S.; Choonia, H.S.; Bajpai, M.; Singh, A.K.; Sinha, A.; Saini, G.; et al. Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models. *bioRxiv* 2021, 2021, 1–26.
64. Momin, T.; Kansagra, K.; Patel, H.; Sharma, S.; Sharma, B.; Patel, J.; Mittal, R.; Sanmukhani, J.; Maithal, K.; Dey, A.; et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. *EClinicalMedicine* 2021, 38, 101020.

